Literatur
-
1
Bouzamondo A, Hulot J S, Sanchez P, Cucherat M, Lechat P.
Beta-blocker
treatment in heart failure.
Fund Clin Pharmacol.
2001;
15
95-109
-
2
Bristow M R, O`Connel J B, Gilbert E M. et al .
Dose-response
of chronic beta-blocker treatment in heart failure from either idiopathic
dilated or ischemic cardiomyopathy.
Circulation.
1999;
89
1632-1642
-
3 Bundesamt. Daten
des Statistischen Bundesamtes. 1998
-
4
Chafin C C, Soberman J E, Demirkan K. et al .
Beta-blockers after myocardial infarction:
Do benefits ever outweigh risks in asthma?.
Cardiology.
1999;
92
99-105
-
5
CIBIS Investigators and Committees .
A
randomized trial of beta-blockade in heart failure. The Cardiac
Insufficiency Bisoprolol Study (CIBIS).
Circulation.
1994;
90
1765-1773
-
6
CIBIS II Investigators and
Committees .
The Cardiac Insufficiency Bisoprolol Study
II (CIBIS II).
Lancet.
1999;
353
9-13
-
7
Cleland J GF.
Health
economic consequences of the pharmacological treatment of heart
failure.
Eur Heart J.
1998;
19
P32-P39
-
8
Anonymous .
Consensus
Recommendations for the Management of Chronic Heart Failure.
Am
J Cardiol.
1999;
83
2A-38A
-
9
Costantini O, Huck K, Carlson M. et al .
Impact of a Guideline-Based Disease Management
Team on Outcomes of Hospitalized Patients with Congestive Heart
Failure.
Arch Intern Med.
2001;
161
177-182
-
10
Dinkel R, Büchner K, Holtz J.
Chronische
Herzinsuffizienz. Sozioökonomische Bedeutung in der Bundesrepublik
Deutschland.
Münch Med Wochenschr.
1989;
131
686-689
-
11
Gottlieb S S, McCarter R J, Vogel R A.
Effect of beta-blockade on mortality among
high-risk and low-risk patients after myocardial infarction.
N
Engl J Med.
1998;
339
489-497
-
12
Hobbs F DR, Jones M I, Allan T F. et al .
European survey of primary
care physician perceptions on heart failure diagnosis and management (Euro-HF).
Eur
Heart J.
2000;
21
1877-1887
-
13
Hoppe U C, Erdmann E. et al .
Leitlinien
zur Therapie der chronischen Herzinsuffizienz.
Z Kardiol.
2001;
90
218-237
-
14
Malek M.
Health
economics of heart failure.
Heart.
1999;
82
(Suppl IV)
IV11-IV13
-
15
McMurray J JV, Petrie M C, Murdoch D R. et al .
Clinical epidemiology of heart
failure: public and private health burden.
Eur Heart J.
1998;
19
P 9-16
-
16
MERIT-HF Study Group .
Effect
of metoprolol CR/XL in chronic heart failure: Metoprolol
CR/XL Randomized Intervention Trial in Congestive Heart
Failure (MERIT-HF).
Lancet.
1999;
353
2001-2007
-
17
Packer M, Bristow M R, Cohn J N. et al .
The effect of carvedilol
on morbidity and mortality in patients with chronic heart failure.
N
Engl J Med.
1996;
334
1349-1355
-
18
Packer M, Poole-Wilson P A, Armstrong P W. et al. ATLAS Study Group .
Comparative
effects of low and high doses of the angiotensin-converting enzyme
inhibitor, lisinopril, on morbidity and mortality in chronic heart
failure.
Circulation.
1999;
100
2312-2318
-
19
Packer M, Coats A JS, Fowler M B. et al .
Effect of carvedilol on
survival in severe chronic heart failure.
N Engl J Med.
2001;
344
1651-1658
-
20
Szcucs T D, Schwenkglenks M, Paschen B. et al .
Wirtschaftlichkeit von Bisoprolol in der
Behandlung der Herzinsuffizienz in Deutschland: Eine Analyse auf
der Basis der CIBIS II Studie.
Med Klin.
2000;
95
663-671
-
21
UK Prospective Diabetes Study
(UKPDS) Group .
Efficacy of atenolol and captopril in
reducing risk of macrovascular and microvascularcomplications in
type 2 diabetes: UKPDS 39.
BMJ.
1998;
317
713-720
-
22
Völler H, Klein G, Gohlke H. et al .
Sekundärprävention Koronarkranker nach
stationärer Rehabilitation.
Dtsch Med Wochenschr.
2000;
125
1457-1461
-
23
Waagstein F, Bristow M R, Swedberg K. et al .
Beneficial effect of metoprolol in idiopathic
dilated cardiomyopathy.
Lancet.
1993;
342
1441-1446
Dr. med. D. H. Antoni
Medizinische Klinik I, Städtisches Krankenhaus
München-Bogenhausen
Englschalkinger Str. 77
81925 München
Telefon: 089/9270-2234
Fax: 089/9270-2253
eMail: DAntoni@gmx.de
